USFDAJun 15, 2026, 09:01 AM
Waldencast's Obagi Medical gets FDA approval for saypha® ChIQ™ HA gel
AI Summary
Waldencast plc announced that its Obagi Medical brand received U.S. FDA approval for Obagi® saypha® ChIQ™ injectable hyaluronic acid gel. This new product expands Obagi Medical's portfolio in the fast-growing U.S. dermal filler market, building on the success of Obagi® saypha® MagIQ™. The approval is a significant step in Waldencast's strategy to establish Obagi as a leader in advanced skincare and medical aesthetics, aiming to provide comprehensive skin transformation solutions.
Key Highlights
- FDA approved Obagi® saypha® ChIQ™ injectable HA gel for Obagi Medical.
- Product indicated for cheek augmentation and midface contour deficiencies in patients over 21.
- Expands Obagi Medical's portfolio in the fast-growing U.S. dermal filler category.
- ALOHA Program data shows 94% of injectors believe Obagi® saypha® MagIQ™ complements options.
- 42.6% of practices using Obagi® saypha® MagIQ™ have evaluated Obagi skincare.
- Croma-Pharma, developer, has produced over 130 million saypha® syringes globally.
Price Impact
More from WALD